Get the app!
Back to Trades
Total Value
$NaN
Filing Date
Jul 23, 2026
1 transactions

Trade Summary

On Jul 23, 2026, Aghazadeh Behzad, Director, reported $NaN of Scribe Therapeutics, Inc. (SCTX) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Company Information

Ticker Symbol
SCTX
CIK
0001853921

Insider Information

Role
Director
Location
NEW YORK, NY

Filing Details

Filing Date
Jul 23, 2026
Transaction Date
Jul 23, 2026
Accession Number
0000902664-26-003226
Form Type
3

Want live alerts when Aghazadeh Behzad trades again?

Download Insider Trades to track SCTX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

Footnotes

  1. (F1)The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"). Behzad Aghazadeh ("Dr. Aghazadeh") serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures", and together with Avoro Capital Advisors and Dr. Aghazadeh, the "Reporting Persons").
  2. (F2)The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.